Dignitana manufactures and markets the clinically superior DigniCap Scalp Cooling System to minimize hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate, and gynecological cancers. FDA cleared since 2015, DigniCap provides a significant quality of life improvement for thousands of patients each year.

"We appreciate this recognition of our commitment to innovation and excellence as we continue to grow our business to provide DigniCap to even more patients," said Catarina Löwenadler, Dignitana CEO. Our latest generation of the Swedish innovation DigniCap Delta is unique on the market, powered by efficient thermoelectric cooling, and manufactured in Dallas, USA.

Presented by The Hunt Institute for Engineering & Humanity of Southern Methodist University, the Inclusive Economy Consortium and their partners, the award program was launched this year to shine a spotlight on the heart of social and environmental impact leaders in Texas, recognizing those who prove that impact enterprises can be a force for good and have the greatest potential for scaled impact.

Scalp cooling is recognized internationally as a standard of care and quality of life advancement for cancer patients and is listed as a treatment recommendation in the clinical practice guidelines published by  National Comprehensive Cancer Network (https://nccn.org/)® (NCCN®), European Society for Medical Oncology (https://www.annalsofoncology.org/article/S0923-7534(20)43157-6/fulltext) (ESMO), and Cancer Australia (https://www.guidancebreastcancer.gov.au/sites/default/files/guidelines/GEBC_Recommendations%20and%20practice%20points_Pdf_Sept%202020.pdf).